Platelets (Nov 2021)
Rivaroxaban reduces thromboxane induced platelet aggregation - the forgotten compass arm?
- Lisa Dannenberg,
- René M‘Pembele,
- Philipp Mourikis,
- Carolin Helten,
- Saif Zako,
- Samantha Ahlbrecht,
- Hannah Richter,
- Dorothee Zikeli,
- Marcel Benkhoff,
- Ragnar Huhn-Wientgen,
- Manuela Thienel,
- Bodo Levkau,
- Malte Kelm,
- Tobias Petzold,
- Amin Polzin
Affiliations
- Lisa Dannenberg
- University Duesseldorf
- René M‘Pembele
- University Hospital Duesseldorf
- Philipp Mourikis
- University Duesseldorf
- Carolin Helten
- University Duesseldorf
- Saif Zako
- University Duesseldorf
- Samantha Ahlbrecht
- University Duesseldorf
- Hannah Richter
- University Duesseldorf
- Dorothee Zikeli
- University Duesseldorf
- Marcel Benkhoff
- University Duesseldorf
- Ragnar Huhn-Wientgen
- University Hospital Duesseldorf
- Manuela Thienel
- Ludwig-Maximilians- University Munich
- Bodo Levkau
- University Hospital Düsseldorf, Heinrich Heine University Düsseldorf
- Malte Kelm
- University Duesseldorf
- Tobias Petzold
- Ludwig-Maximilians- University Munich
- Amin Polzin
- University Duesseldorf
- DOI
- https://doi.org/10.1080/09537104.2021.1905159
- Journal volume & issue
-
Vol. 32,
no. 8
pp. 1126 – 1128
Abstract
No abstracts available.Keywords
- aggregation
- aspirin
- major adverse cardiovascular and cerebrovascular events
- platelet inhibition
- rivaroxaban
- thromboxane
